Mizuho Securities Has Just Reaffirmed $54.0000 Target Price Per Share on Eagle Pharmaceuticals (NASDAQ:EGRX) stock, While They’ve Also Reiterated Their “Sell” Rating

May 18, 2018 - By Jimmy Baldridge

Eagle Pharmaceuticals (NASDAQ:EGRX) Rating Reaffirmed

Eagle Pharmaceuticals (NASDAQ:EGRX) just had their share rating of a ‘”Sell”‘ issued by research analysts at Mizuho Securities, who now has a $54.0000 TP on the $1.02 billion market cap company or a -21.27 % downside potential. This key information was revealed to clients and investors in a research report on Thursday morning.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Coverage

Among 3 analysts covering Eagle Pharmaceuticals (NASDAQ:EGRX), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Eagle Pharmaceuticals has $79.0 highest and $37.0 lowest target. $63.33’s average target is -7.67% below currents $68.59 stock price. Eagle Pharmaceuticals had 6 analyst reports since December 18, 2017 according to SRatingsIntel. RBC Capital Markets maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Monday, February 26. RBC Capital Markets has “Buy” rating and $71.0 target. The firm has “Buy” rating given on Tuesday, January 30 by Piper Jaffray. Mizuho maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) rating on Wednesday, March 21. Mizuho has “Sell” rating and $40.0 target. The firm has “Sell” rating by Mizuho given on Monday, February 26. The firm has “Sell” rating given on Monday, May 7 by Mizuho. Mizuho maintained the stock with “Sell” rating in Monday, December 18 report.

The stock increased 1.27% or $0.86 during the last trading session, reaching $68.59. About 249,008 shares traded. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has declined 36.05% since May 18, 2017 and is downtrending. It has underperformed by 47.60% the S&P500.

Analysts await Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) to report earnings on August, 8. They expect $0.77 earnings per share, up 133.33 % or $0.44 from last year’s $0.33 per share. EGRX’s profit will be $11.43M for 22.27 P/E if the $0.77 EPS becomes a reality. After $0.17 actual earnings per share reported by Eagle Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 352.94 % EPS growth.

Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company has market cap of $1.02 billion. The firm offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. It has a 20.98 P/E ratio. The Company’s product candidates includes include EP-4104, a dantrolene sodium for exertional heat stroke; EGL-4104-C-1702, dantrolene sodium for drug induced hyperthermia; EP-5101 for lung cancer and mesothelioma; and EGL-5385-C-1701 (fulvestrant) for breast cancer.

More notable recent Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) news were published by: Nasdaq.com which released: “Market Trends Toward New Normal in Agios Pharmaceuticals, Corcept Therapeutics, Prestige Brand, Virtu Financial …” on May 17, 2018, also Streetinsider.com with their article: “Eagle (EGRX) Denied Unique Ryanodex J-Code – Mizuho” published on May 07, 2018, Streetinsider.com published: “Eagle Pharmaceuticals (EGRX) Misses Q1 EPS by 16c, Miss on Revenues” on May 10, 2018. More interesting news about Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) were released by: Streetinsider.com and their article: “Eagle Pharmaceuticals (EGRX) Says it was Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to …” published on May 16, 2018 as well as Businesswire.com‘s news article titled: “Eagle Pharmaceuticals, Inc. Granted Final FDA Approval for Bendamustine Hydrochloride Ready-to-Dilute Solution in …” with publication date: May 16, 2018.

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: